About Dr. Chang Jianhua
Dr. Chang Jianhua (常建华) is an esteemed medical oncologist and postdoctoral researcher, serving as Chief Physician and Director of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS), Shenzhen Hospital. Bringing three decades of specialized thoracic medical oncology experience to one of China's most advanced national cancer institutions, Dr. Chang is widely celebrated as the visionary founder of Shenzhen's first dedicated Rare-Mutation Lung Cancer Clinic (肺癌罕见突变门诊).
Throughout his 30-year clinical career, Dr. Chang has concentrated on the precision management of complex lung and esophageal cancers. He is a recognized national pioneer in deciphering rare driver gene mutations, matching atypical genomic alterations with next-generation targeted therapeutics, and leading pivotal clinical trials that provide patients with actionable solutions when standard first-line therapies prove ineffective.
Core Clinical Specializations & Oncological Innovations
1. Pioneer of Shenzhen's First Rare-Mutation Lung Cancer Clinic
While standard lung cancer care primarily addresses common mutations like EGFR and ALK, approximately 10% to 15% of non-small cell lung cancer (NSCLC) patients harbor rare or atypical alterations. Dr. Chang founded the region's first specialized rare-mutation clinic, establishing standardized diagnostic and therapeutic pathways for patients with ROS1 fusions, MET exon 14 skipping and MET amplification, RET fusions, HER2 mutations/insertions, BRAF V600E alterations, KRAS G12C, and NTRK gene fusions.
2. Advanced Thoracic Medical Oncology (Lung & Esophageal Cancers)
Dr. Chang brings 30 years of seasoned frontline clinical mastery to thoracic medical oncology. He specializes in designing integrated systemic care plans for locally advanced and metastatic NSCLC, small cell lung cancer (SCLC), and advanced esophageal carcinomas, seamlessly combining molecular targeted therapy, immunotherapy, and individualized maintenance protocols.
3. Overcoming Acquired Resistance & Salvage Targeted Strategies
Acquired resistance inevitably develops during targeted kinase inhibitor treatment. Dr. Chang utilizes comprehensive liquid biopsy (ctDNA) and re-biopsy next-generation sequencing (NGS) to distinguish on-target solvent-front mutations from bypass activation pathways (such as MET, HER2, or PI3K) and histological small-cell transformations. By implementing precision combination strategies and next-generation antibody-drug conjugates (ADCs), he consistently re-establishes disease control for heavily pretreated patients.
4. Immuno-Oncology & Novel Therapeutic Regimens
Dr. Chang possesses deep expertise in the safe, effective deployment of immune checkpoint inhibitors (anti-PD-1/PD-L1) for solid tumors. His clinical protocols emphasize biomarker-driven selection (PD-L1 expression, TMB, immune microenvironment signatures) to avoid hyper-progression and toxic immune-related adverse events (irAEs), achieving durable remissions for advanced thoracic cancer patients.
Academic Leadership & Landmark Publications (2024–2025)
Dr. Chang is an active clinical trialist and researcher whose translational investigations advance global thoracic oncology knowledge:
- High-Impact Publications: Throughout 2024 and 2025, Dr. Chang published seminal cohort studies in the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), evaluating real-world therapeutic outcomes, genomic co-alterations, and resistance profiles in rare-target lung cancers.
- Leading Phase II Clinical Trials: Serving as Principal Investigator (PI), Dr. Chang leads multiple national Phase II multicenter clinical trials evaluating novel targeted kinase inhibitors, brain-penetrant compounds, and bispecific antibodies specifically tailored for ROS1-positive, MET-altered, and HER2-mutated non-small cell lung cancer.
- National Committee Leadership: He actively participates in national thoracic oncology working groups, contributing to national expert consensus statements and clinical practice guidelines across China.
Cancer Hospital CAMS, Shenzhen Hospital Profile
Operated under the direct management of the Cancer Hospital of the Chinese Academy of Medical Sciences (National Cancer Center of China), the Shenzhen Hospital serves as a premier national medical hub in South China. Its Department of Medical Oncology, directed by Dr. Chang Jianhua, features cutting-edge molecular genomics and liquid biopsy laboratories, dedicated Phase I-III clinical trial wards, and comprehensive multidisciplinary consultation infrastructure.
Why International Patients Choose Dr. Chang Jianhua
- Dedicated Rare-Mutation Authority: Dedicated expertise in ROS1, MET, RET, HER2, and unusual genomic alterations rarely encountered in standard community cancer centers.
- 30 Years of Senior Oncology Wisdom: Balanced clinical insight honed over three decades prevents empirical trial-and-error, ensuring rapid deployment of the most effective regimens.
- Access to Active Targeted Clinical Trials: Qualifying patients with rare mutations or multi-drug resistance gain early access to next-generation targeted compounds.
- Convenient Greater Bay Area Hub: Strategically situated in Shenzhen, offering seamless international transit connections via Hong Kong and Shenzhen International Airports.
The Patient Journey: Navigating Care with CMCS
China Medical Concierge – Shanghai (CMCS) coordinates access for international patients seeking expert consultation with Dr. Chang Jianhua in Shenzhen:
- Step 1: Molecular Dossier & NGS Review: Patients submit previous clinical records, NGS genetic sequencing reports, and contrast-enhanced imaging scans (CT, MRI, PET-CT) for preliminary genomic verification.
- Step 2: Strategy Review & Trial Pre-Screening: CMCS coordinates an initial specialist case assessment with Dr. Chang's team to identify available targeted therapies or active Phase II clinical trial matching.
- Step 3: Medical Visa, Transit & Accommodations: We issue medical visa documentation, arrange airport greeting in Shenzhen or Hong Kong, and coordinate executive lodging near CAMS Shenzhen Hospital.
- Step 4: Dedicated Bilingual Medical Liaison: An experienced clinical coordinator accompanies you to outpatient consultations, repeat liquid biopsy testing, imaging diagnostics, and pharmacy dispensations.
- Step 5: Post-Treatment Monitoring & Continuity of Care: Following initial treatment, CMCS coordinates long-term tracking of follow-up blood work, remote imaging reviews, and physician follow-up consultations.
Frequently Asked Questions
What are rare lung cancer mutations, and why do they require specialized clinics?
Rare mutations (such as ROS1, MET, RET, HER2, and NTRK) represent subsets of lung cancer where standard chemotherapy or single-agent immunotherapy is often suboptimal. Because each subtype requires dedicated targeted kinase inhibitors, a specialized clinic ensures accurate diagnostic testing and rapid access to specific targeted drugs and clinical trials.
What if my local hospital does not have targeted drugs for my specific rare mutation?
Through CAMS Shenzhen Hospital and active national clinical trials, Dr. Chang's clinic provides access to next-generation targeted drugs, clinical trials, and novel combination therapies that may not yet be available in standard overseas clinics.
What records are needed before booking an evaluation?
Full comprehensive next-generation sequencing (NGS) reports (tissue or liquid biopsy), histological pathology reports, digital DICOM files of recent CT or PET scans, and a detailed timeline of previous systemic therapies.
How long should international patients stay in Shenzhen?
An initial outpatient consultation, genomic restaging, and personalized treatment plan formulation typically require 3 to 5 business days in Shenzhen. If initiating a new targeted agent or enrolling in a clinical trial, a stay of 1 to 2 weeks is recommended for initial monitoring.
Schedule Your Consultation with Dr. Chang Jianhua
If you or a loved one requires an authoritative second opinion for lung cancer, esophageal cancer, or rare oncogenic driver mutations (ROS1, MET, RET, HER2), contact our medical concierge team today.
Contact CMCS Medical Concierge:
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
- Website: www.medicalsh.com
0 commenti